Detection of 5q31.2 - 5q33.1 deletions
Main indication:
AML-MDS.
Test usage:
Prognostic investigation in patients with myelodysplasia or other myeloid malignancies. Among the patients with myelodysplastic syndromes (MDS), 45-50% have a least one chromosome rearrangement, the most common of which can be detected using this fluorescence in situ hydridization (FISH) panel (-5/5q-,-7/7q-,+8,20q-).